Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Cardium Therapeutics, Inc. (CXM) Addresses Two Major Diseases Of The Digital Age 0 comments
    Jun 11, 2013 3:08 PM | about stocks: CXM

    When we contemplate the effects that digital electronics has had on health, we are likely to think of the truly amazing progress made in things like medical diagnostics or medical information processing and communication. What is becoming increasingly clear, however, are the negative effects that our move to a digital world has produced. Although research in this area is still limited and ongoing, there now seems to be little doubt that the sedentary lifestyle encouraged by the growing, almost addictive use of computers and mobile devices is seriously threatening our nation's and ultimately the world's health. Two of the most significant areas of concern are diabetes and heart disease.

    Even a cursory look at statistics for diagnosed diabetes in the U.S. reveals a sharp rise in cases, beginning around 1990 when personal computers and the Web first began working their way into modern daily life. Within two decades, the number of diabetes cases in the U.S. had tripled. Obesity has been related directly to lack of activity in conjunction with sugary foods, and this condition has risen dramatically, more than doubling in children. Obesity is seen as a leading contributor for both diabetes and heart disease. Although new high-tech treatments have been able to help stem deaths from heart disease, it is still a growing and deadly disease, and remains the leading cause of death.

    Cardium Therapeutics, a California-based health sciences and regenerative medicine company, is one of the few companies with a focus on both of these major markets. The company's primary lead product, Generx, is designed to do what no traditional heart treatment medications can do, actually stimulate the growth of blood vessels around the heart in order to enhance myocardial blood flow in heart disease patients. Other drug therapies are designed simply to reduce pain. Excellagen, Cardium's lead commercial product, already FDA-cleared, is designed to accelerate the healing process of things like diabetic foot ulcers, a critical problem for diabetes patients. An added benefit is that it can improve healing of many other types of wounds.

    For additional information, visit www.CardiumTHX.com

    Please see disclaimer on the MissionIR website
    http://www.missionir.com/disclaimer.html

    Stocks: CXM
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.